Holen Sie sich die Stockscreener-App
5.67
7.59%
0.40
Schlusskurs vom Vortag:
$5.27
Offen:
$5.32
24-Stunden-Volumen:
140.43K
Relative Volume:
0.41
Marktkapitalisierung:
$17.69M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-68.80M
KGV:
-4.8462
EPS:
-1.17
Netto-Cashflow:
$-59.06M
1W Leistung:
-4.79%
1M Leistung:
+1,350%
6M Leistung:
+851.50%
1J Leistung:
+553.23%
1-Tages-Spanne:
$5.32
$5.86
1-Wochen-Bereich:
$5.1239
$6.4096
52-Wochen-Spanne:
$0.257
$7.63
Passage Bio Inc Stock (PASG) Company Profile
Firmenname
Passage Bio Inc
Sektor
Branche
Telefon
(267) 866-0312
Adresse
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Vergleichen Sie PASG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
5.67 | 18.58M | 0 | -68.80M | -59.06M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-29 | Fortgesetzt | Wedbush | Outperform |
| 2024-09-03 | Eingeleitet | Rodman & Renshaw | Buy |
| 2022-03-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-01-19 | Herabstufung | Goldman | Buy → Neutral |
| 2021-07-01 | Eingeleitet | Raymond James | Outperform |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-03-04 | Hochstufung | Goldman | Neutral → Buy |
| 2021-02-04 | Eingeleitet | Guggenheim | Buy |
| 2021-01-25 | Eingeleitet | Wedbush | Outperform |
| 2021-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-11 | Eingeleitet | Citigroup | Neutral |
| 2020-08-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-25 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-25 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-03-24 | Eingeleitet | Cowen | Outperform |
| 2020-03-24 | Eingeleitet | Goldman | Buy |
| 2020-03-24 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Passage Bio Inc Aktie (PASG) Neueste Nachrichten
What drives Passage Bio Inc. stock priceConsistent double returns - jammulinksnews.com
Passage Bio Inc. Stock Analysis and ForecastGame-changing returns - Autocar Professional
What analysts say about Passage Bio Inc. stockExtraordinary earning power - jammulinksnews.com
Is Passage Bio Inc. a good long term investmentOutstanding trading profits - jammulinksnews.com
Why Passage Bio Inc. stock attracts strong analyst attentionTriple Return With Stability - Newser
Gm1 Gangliosidosis Treatment Market Exclusive Report with - openPR.com
Passage Bio Approves 1-for-20 Reverse Stock Split to Maintain Nasdaq Compliance - MSN
Fierce Biotech Layoff Tracker 2025: Sarepta lays off 500 staffers; GSK trims R&D team - Fierce Biotech
How Passage Bio Inc. stock performs during market volatility5x Profit Potential - Newser
What makes Passage Bio Inc. stock price move sharplyFree Consultation - Newser
Passage Bio Announces Reverse Stock Split Effective July 14 - TipRanks
Passage Bio's Reverse Split: A Desperate Move or a Clever Play? - AInvest
Passage Bio Announces 1-for-20 Reverse Stock Split - citybiz
Passage Bio's Reverse Stock Split: A Necessary Gamble for Survival? - AInvest
Passage Bio announces 1-for-20 reverse stock split to regain compliance - Investing.com
Passage Bio Announces 1-for-20 Reverse Stock Split to Regain Nasdaq Compliance - Nasdaq
Passage Bio Announces Major 1-for-20 Reverse Split, Shares Reduced from 62M to 3M - Stock Titan
Frontotemporal Dementia Market Sees Rise in Precision Medicine and Gene Therapy Approaches | DelveInsight - The Malaysian Reserve
Passage Bio (PASG) Announces Key Updates from PBFT02 Clinical Tr - GuruFocus
Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update - GlobeNewswire
Annovis Bio Secures NYSE Approval to Regain Compliance with Listing Standards - MyChesCo
Passage Bio, Inc. (NASDAQ:PASG) Stake Cut by Two Sigma Investments LP - Defense World
Two Sigma Investments LP Makes New Investment in BioVie Inc. (NASDAQ:BIVI) - Defense World
10,923 Shares in Annovis Bio, Inc. (NYSE:ANVS) Bought by Two Sigma Investments LP - Defense World
American Battery Technology (NASDAQ:ABAT) Shares Purchased by Two Sigma Investments LP - Defense World
Millennium Management LLC Purchases Shares of 37,704 Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Squarepoint Ops LLC Has $36,000 Stake in Passage Bio, Inc. (NASDAQ:PASG) - Defense World
Semrush Holdings, Inc. (NASDAQ:SEMR) Shares Purchased by Bank of America Corp DE - Defense World
Lumina Gold (OTCMKTS:LMGDF) Trading Down 0.3% – Here’s Why - Defense World
Obsidian Energy (OTCMKTS:OBELF) Shares Up 2.7% – Here’s Why - Defense World
Carbios SAS (OTCMKTS:COOSF) Stock Price Up 5% – Here’s Why - Defense World
Suncrest Bank (OTCMKTS:SBKK) Shares Up 1% – Should You Buy? - Defense World
Color Star Technology (NASDAQ:CSCW) Trading 0.5% Higher – Here’s What Happened - Defense World
Inventiva (NASDAQ:IVA) Stock Price Up 0.8% – Here’s Why - Defense World
Fury Gold Mines (NYSEAMERICAN:FURY) Stock Price Down 3.2% – Here’s Why - Defense World
Nano Magic (OTCMKTS:NMGX) Shares Up 5% – What’s Next? - Defense World
Jane Street Group LLC Grows Holdings in Passage Bio, Inc. (NASDAQ:PASG) - Defense World
Pre-market Movers: BDTX, CRGX, PASG, RGC... - RTTNews
Layoff Tracker: Capsida Downsizes as Part of Shift to Clinical-Stage Company - BioSpace
Passage Bio, Inc. (NASDAQ:PASG) Shares Purchased by Northern Trust Corp - Defense World
Finanzdaten der Passage Bio Inc-Aktie (PASG)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):